by Raynovich Rod | Apr 26, 2018 | Biopharmaceuticals
Update 4/30… Vertex Pharmaceuticals (VRTX) Beat Consensus by 4% Financial Results: CF Revenues rose 33% Q’18 o Q’17 from $481M to $638M; GAAP net income down 15% ,$210M from $241M. Two Phase 3 triple combination clinical development programs are...
by Raynovich Rod | Apr 24, 2018 | Biopharmaceuticals
Update 4/25: Investors May See Value in Large Cap Biotech Amgen (AMGN) up 1.68%. Biogen (BIIB) holds Tuesday lows of $262 Up 2.78% today. IBB flat at $103.26 More earnings tomorrow but it is all about technicals holding the recent bottom. ========== Biotech Sector...
by Raynovich Rod | Apr 23, 2018 | Biopharmaceuticals
Speculative Biotech Stocks Sell-Off in Profit Taking: Gene Editing Biotech stocks held current levels but small caps and speculative stocks sold off with the XBI down 1%. Most large caps were in the green with an upgrade from Goldman Sachs helping Merck (MRK) up 2.4%...
by Raynovich Rod | Apr 17, 2018 | Biopharmaceuticals
Updates: 4/19/18 GWPH hits $143 new high, then sold off holding $134 level, after big move from $105 on cannabis drug for severe epilepsy FDA Advisory go ahead. Biotechs broadly in the red except CRSP up 6.4% and NVCR up 5%. AstraZeneca (AZN) gained US approval for...
by Raynovich Rod | Apr 9, 2018 | Biopharmaceuticals
Updates 4/11/18 Biotechs Holding Above Recent Bottom 4/6/18 FBT up 2.8% over 5 days, up 6% YTD XBI up 1.77% over 5 days, up 2.19% YTD IBB down 0.72% over 5 days, down 3.67% YTD Busted Biotechs Review In our “Busted Biotechs” article we said that the XBI...
by Raynovich Rod | Apr 4, 2018 | 2025 Rayno Biopharmaceuticals Portfolio
4/17/18 Latest portfolio changes are working: CELG at $88, XBI at $84. all based on technicals. ========== Busted Biotech Stocks Get No Help From the Overall Market 4/8 Update XBI down 3% on 4/6 and BELOW SMA 20 AT $82.90. Bellwether Mid-Caps red screen-two up stocks...
by Raynovich Rod | Mar 30, 2018 | Biopharmaceuticals
2018 Large Cap Biopharmaceuticals – Performance Compared to ETFs It has been a rough start for large cap biopharmaceutical stocks but the ETFs (FBT) and (XBI) still outperformed the SPY YTD and over 12 months. Most Individual stocks lagged unless you owned...
by Raynovich Rod | Mar 29, 2018 | Biopharmaceuticals
4/2/18 12:30P Update Biotechs break through 2018 support levels with XBI now needs to hold December lows at $80. IBB at double bottom hit in November/December at $102 level. Watch Mid-Cap list below for sector weakness. ============== Biotech Bull Market Is Intact...
by Raynovich Rod | Mar 25, 2018 | Biopharmaceuticals, Macro
Sell-Off Gets Scary–NASDAQ Futures Still Down at 1:30A EDT 3/28 Double Bottom -Double Top on XBI and Testing February Lows at $87 Another Sell-Off=Tuesday Movers 3/27/18 Large Caps % Up-NONE FBT Down 3.23%, IBB Down 2.77% to $105.12, QQQ down 3.24%, XBI down...
by Raynovich Rod | Mar 20, 2018 | Biopharmaceuticals
Update-2…3/22 ABBV News Kills Momentum of Biotech Stocks 12:30P EDT Abbvie (ABBV) down 13.5 % on disappointing results on blood cancer drug. The big issue is that the drug was recently acquired for $5.8B from Stemcentrx back in 2016. The Company will not seek...
